Intercept pharmaceuticals, inc. (ICPT)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Revenue

72,652

71,500

61,950

66,300

52,252

53,280

46,986

43,575

35,963

-

40,889

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total revenue

-

-

-

-

-

-

-

-

-

-

41,334

30,887

21,048

-

5,177

5,520

445

-

445

445

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses:
Cost of sales

852

2,474

487

677

574

1,007

519

713

280

823

172

279

97

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Selling, general and administrative

98,558

93,680

76,828

69,683

77,227

70,971

56,812

65,224

62,467

84,335

61,356

66,925

61,082

76,214

52,802

48,715

95,865

60,388

24,742

20,974

13,138

11,858

9,136

7,955

5,651

4,729

3,115

2,890

2,396

2,183

991

943

1,059

1,035

1,154

894

1,125

Research and development

56,687

64,636

60,168

59,599

58,396

63,273

47,941

47,415

48,672

57,498

45,977

44,192

43,832

51,602

35,411

34,900

31,980

28,948

27,487

28,295

27,966

23,718

27,381

14,919

14,292

9,583

8,392

5,132

4,832

4,786

3,318

5,018

3,059

4,163

2,512

2,521

2,229

Total operating expenses

156,097

160,790

137,483

129,959

136,197

135,251

105,272

113,352

111,419

142,656

107,505

111,396

105,011

127,816

88,213

83,615

127,845

89,337

52,229

49,269

41,103

35,577

36,517

22,874

19,943

14,312

11,507

8,023

7,229

6,969

4,309

5,961

4,118

5,198

3,666

3,415

3,355

Operating loss

-83,445

-89,290

-75,533

-63,659

-83,945

-81,971

-58,286

-69,777

-75,456

-104,969

-66,171

-80,509

-83,963

-114,007

-83,036

-78,095

-127,400

-

-51,784

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income (expense):
Revaluation of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-55,795

226,626

-1,569

20,756

5,572

3,682

-24,187

-1,417

301

677

776

174

72

21

Interest expense

11,777

11,626

11,795

9,884

7,839

7,754

7,671

7,589

7,509

7,431

7,354

7,279

7,207

-

7,065

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income, net

2,239

2,758

2,495

2,123

1,514

1,720

1,503

2,173

1,375

1,128

924

1,224

1,240

1,096

1,286

796

726

-

889

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Foreign currency loss on liquidation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

191

-

-

-

-

-

Other income, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

930

272

-

228

104

136

-30

121

-286

296

61

16

7

2

17

10

19

0

Total other (expense), net

-9,538

-8,868

-9,300

-7,761

-6,325

-6,034

-6,168

-5,416

-6,134

-6,303

-6,430

-6,055

-5,967

-6,035

-5,779

796

726

636

889

930

272

307

228

55,899

-226,490

1,538

-20,634

-5,858

-3,386

-24,126

-1,400

117

680

793

184

92

22

Net loss

-92,983

-98,158

-84,833

-71,420

-90,270

-88,005

-64,454

-75,193

-81,590

-111,272

-72,601

-86,564

-89,930

-120,042

-88,815

-77,299

-126,674

-88,254

-50,895

-47,894

-39,386

-34,824

-35,843

33,470

-246,028

-12,367

-31,737

-13,476

-10,210

-30,690

-5,186

-5,085

-2,679

-3,645

-2,840

-2,918

-3,332

Net loss per common and potential common share:
Dividends on preferred stock, not declared

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

130

1,000

750

750

750

750

750

750

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-10,210

-30,820

-6,186

-5,835

-3,429

-4,395

-3,590

-3,668

-4,082

Basic and diluted

-2.86

-2.99

-2.59

-2.28

-3.03

-2.88

-2.18

-2.58

-3.22

-4.42

-2.89

-3.46

-3.61

-4.84

-3.59

-3.14

-5.17

-3.69

-2.10

-1.99

-1.78

-

-1.69

-

-12.61

-

-1.65

-

-0.62

-2.02

-1.86

-1.75

-1.03

-1.32

-1.08

-1.10

-1.23

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1.60

-

-

-

-0.79

-

-

-

-

-

-

-

-

-

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1.51

-

-

-

-0.79

-

-

-

-

-

-

-

-

-

Weighted average common and potential common shares outstanding:
Basic and diluted

32,561

32,823

32,717

31,316

29,760

29,733

29,615

29,199

25,309

25,153

25,104

25,028

24,931

24,807

24,738

24,612

24,495

24,374

24,215

24,014

22,171

-

21,260

-

19,504

-

19,198

-

16,558

15,223

3,329

3,329

3,329

3,329

3,329

3,329

3,329

Weighted average shares outstanding, basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

20,965

-

-

-

16,970

-

-

-

-

-

-

-

-

-

Weighted average shares outstanding, diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

22,204

-

-

-

16,970

-

-

-

-

-

-

-

-

-

Other comprehensive gain (loss):
Unrealized gain (loss) on investment securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-245

-

-

-

-

-

-

-

-

Total comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-10,455

-

-

-

-

-

-

-

-

Product [Member]
Revenue

72,652

70,284

61,545

65,894

51,847

52,874

46,581

43,169

35,158

-

-

30,441

20,603

-

4,732

75

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

License [Member]
Revenue

-

1,216

405

406

405

406

405

406

805

445

445

446

445

447

445

5,445

445

447

445

445

1,445

446

445

445

405

405

405

405

405

405

523

758

758

758

640

405

0